Dare Bioscience Inc
NASDAQ:DARE

Watchlist Manager
Dare Bioscience Inc Logo
Dare Bioscience Inc
NASDAQ:DARE
Watchlist
Price: 1.96 USD -1.51% Market Closed
Market Cap: 28m USD

Dare Bioscience Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Dare Bioscience Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Dare Bioscience Inc
NASDAQ:DARE
EPS (Diluted)
-$1
CAGR 3-Years
-55%
CAGR 5-Years
-8%
CAGR 10-Years
22%
Johnson & Johnson
NYSE:JNJ
EPS (Diluted)
$10
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
EPS (Diluted)
$2
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
EPS (Diluted)
$1
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
EPS (Diluted)
$7
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
EPS (Diluted)
$20
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
25%
No Stocks Found

Dare Bioscience Inc
Glance View

Market Cap
27.3m USD
Industry
Pharmaceuticals

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2014-04-10. The firm is focused on advancing products for women's health. The company offers a portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. Its first product, XACIATO, is a vaginal gel used for the treatment of bacterial vaginosis in females having 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1, and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-RH1, ADARE-204, and ADARE-214. Ovaprene, is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.

DARE Intrinsic Value
10.13 USD
Undervaluation 81%
Intrinsic Value
Price

See Also

What is Dare Bioscience Inc's EPS (Diluted)?
EPS (Diluted)
-1.1 USD

Based on the financial report for Sep 30, 2025, Dare Bioscience Inc's EPS (Diluted) amounts to -1.1 USD.

What is Dare Bioscience Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
22%

Over the last year, the EPS (Diluted) growth was -150%. The average annual EPS (Diluted) growth rates for Dare Bioscience Inc have been -55% over the past three years , -8% over the past five years , and 22% over the past ten years .

Back to Top